FDA Approves Scholar Rock’s ISEMBYLD for Spinal Muscular Atrophy

Key Facts

In a move that marks a significant shift in the treatment of genetic disorders, the U.S. Food and Drug Administration (FDA) has approved ISEMBYLD (apitegromab-mstn) developed by Scholar Rock. This therapy stands as the first muscle-targeted treatment for spinal muscular atrophy (SMA) in patients aged two years and older. The approval expands the therapeutic landscape for SMA, positioning the company as a leader in the specialized biotechnology sector.

Per market data, this approval aligns with positive sentiment toward biotech firms focusing on rare diseases, as such regulatory milestones typically unlock significant revenue potential. Regarding stock performance, data shows relative stability in trading leading up to the official announcement, reflecting investor anticipation of the regulatory outcome for apitegromab-mstn from U.S. authorities.

Scholar Rock (SRRK) stood at $55.67 (at close September 10, 2026), after reaching a day high of $56.71. With no immediate catalysts in the upcoming economic calendar specifically for the pharmaceutical sector, investors will watch for the company's commercial rollout plans for ISEMBYLD. The level of $53.86 serves as a technical support based on the day low from the most recent trading session.